Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
Sponsor: Regenerative Ocular Immunobiologics LLC
Summary
A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)
Official title: A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1
Start Date
2025-01-10
Completion Date
2026-12
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Interventions
d-MAPPS
Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.
Placebo
Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.
PI and Patient Masked
Both the PI and the participant are masked on the drug administered.
Locations (5)
Beverly Hills Institute of Ophthalmology
Beverly Hills, California, United States
Beach Eye Medical Group
Huntington Beach, California, United States
Regenerative Ocular Immunobiologics, LLC.
Palm Harbor, Florida, United States
Glenn Eye Center
Lexington, Kentucky, United States
Eyewell, LLC.
Boston, Massachusetts, United States